Pfizer Inc. $PFE Shares Bought by Tectonic Advisors LLC

Tectonic Advisors LLC raised its position in Pfizer Inc. (NYSE:PFE) by 22.1% in the 2nd quarter, Holdings Channel.com reports. The fund owned 298,687 shares of the biopharmaceutical company’s stock after acquiring an additional 54,068 shares during the quarter. Tectonic Advisors LLC’s holdings in Pfizer were worth $7,240,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer during the first quarter worth $27,000. North Capital Inc. acquired a new stake in shares of Pfizer during the first quarter worth $28,000. Bayforest Capital Ltd acquired a new stake in shares of Pfizer during the first quarter worth $28,000. Horizon Financial Services LLC acquired a new stake in shares of Pfizer during the first quarter worth $35,000. Finally, WPG Advisers LLC acquired a new stake in shares of Pfizer during the first quarter worth $35,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 2.3%

PFE stock opened at $25.67 on Thursday. The stock has a market capitalization of $145.95 billion, a P/E ratio of 13.65, a P/E/G ratio of 0.86 and a beta of 0.55. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The firm has a 50-day simple moving average of $24.79 and a 200-day simple moving average of $24.15. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same period in the previous year, the business earned $0.60 EPS. Pfizer’s quarterly revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Morgan Stanley lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Citigroup lifted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday. Finally, Bank of America upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $28.41.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.